And while metformin has been the first-line therapy in treating type 2 diabetes, the FDA announced in 2019 that Rybelsus (semaglutide), a GLP-1, can also be offered as a first-line treatment
CagriSema is filed T2D evidence : Tirzepatide has more extensive T2D trial data GI tolerability : CagriSema has higher overall GI event rates Conclusion# CagriSema and tirzepatide represent different strategies to the same goal: surpassing GLP-1-only weight loss
[DOI] [PMC free article] [PubMed] [Google Scholar] 38.Bhate V, Deshpande S, Bhat D, Joshi N, Ladkat R, Watve S, Fall C, de Jager CA, Refsum H, Yajnik C
doi: 10.1038/pr.2013.199
For most researchers, the two-compound stack represents a clean, manageable protocol without the complexity of managing multiple compounds simultaneously